Enhabit Q1 2025 Earnings Report

Enhabit EPS Results

• Actual EPS: $0.10
• Consensus EPS: $0.07
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Enhabit Revenue Results

• Actual Revenue: $259.90 million
• Expected Revenue: $266.11 million
• Beat/Miss: Missed by -$6.21 million
• YoY Revenue Growth: N/A

Enhabit Announcement Details

• Quarter: Q1 2025
• Date: 5/7/2025
• Time: After Market Closes
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 10:00AM ET

Enhabit (NYSE:EHAB) (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.

The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services. Enhabit’s clinical teams work closely with primary care physicians, hospitals and other care providers to execute tailored care plans, monitor patient progress and adjust treatments as needed. Leveraging proprietary care-management technology, Enhabit aims to streamline clinical workflows, improve care coordination and reduce avoidable hospital readmissions.

Enhabit operates across more than 20 states in both urban and rural markets, having expanded its footprint through a combination of organic growth and strategic acquisitions of regional home health and hospice providers. The company’s leadership team comprises seasoned healthcare executives with decades of experience in home health, hospice and care management. With an emphasis on quality, compliance and patient satisfaction, Enhabit continues to pursue opportunities that strengthen its service capabilities and extend its reach to communities nationwide.

Enhabit Q1 2025 Earnings Call Transcript

Key Takeaways

• Home Health delivered sequential admission growth of 8.1% (with non-Medicare admissions up 7.4% yoy via payer innovation), reduced visits per episode by 6.7%, and drove year-over-year and sequential decreases in cost per patient day.
• Hospice continued its momentum with admissions up 8% yoy, average daily census up 12.3%, a 310 bp improvement in referrals-to-admission conversion, and year-over-year cost per day down 0.8% while opening a new location and advancing 13 de novo projects.
• Consolidated adjusted EBITDA rose 6% sequentially and 5.1% yoy to $26.6 million, lifting margins by 60 bps to 10.2%; Home Health EBITDA margin expanded 140 bps to 19.1% and Hospice margin hit a post-spin high of 25.3%.
• The balance sheet was bolstered by $17 million of free cash flow, $25 million in bank debt paydown, and a leverage ratio of 4.4x—below covenant—unlocking improved pricing and acquisition flexibility.

Presentation

[Operator]

Hello. Good morning, everyone, and welcome to Enhabit Home Health and Hospice's first quarter 2025 earnings conference call. At this time, I'd like to inform all participants that their lines will be in a listen-only mode. After the speaker's remarks, there will be a question-and-answer period. You will be limited to one question and one follow-up question. Today's conference call is being recorded. If you have any objections, you may disconnect at this time. I will now turn the call over to Jobie Williams, Senior Vice President and Treasurer. Mr. Williams, please go ahead.

[Jobie Williams, SVP and Treasurer at Enhabit Home Health and Hospice]

Thank you, Operator, and good morning, everyone. Thank you for joining our call today. With me on the call is Barb Jacobsmeyer, President and Chief Executive Officer, and Ryan Solomon, Chief Financial Officer. Before we begin, if you do not already have a copy, the first quarter earnings release, supplemental information, and related Form 8K filed with the SEC are available on our website at investors.ehab.com. On page two of the supplemental information, you will find the safe harbor statements, which are also set forth on the last page of the earnings release. During the call, we will make forward-looking statements, which are subject to risk and uncertainties, many of which are beyond our control.

[Jobie Williams, SVP and Treasurer at Enhabit Home Health and Hospice]

Certain risks and uncertainties that could cause actual results to differ materially from our projections, estimates, and expectations are discussed in our SEC filing, including our annual report on Form 10-K, which are available on our website. We encourage you to read them. You are cautioned not to place undue reliance on the estimates, projections, guidance, and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain Non-GAAP financial measures. For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information and the earnings release. With that, I'll turn the call over to Barb.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Thanks, Joby. Good morning, and thanks for joining us. In our year-end earnings call, I outlined how executing on 2024 strategies laid a promising foundation for 2025 success. Our team has done a tremendous job in the first quarter building on that foundation. Our first quarter home health performance is the result of executing on our payer contract initiatives. We started 2025 in a stronger position with our payer contract and were able to fully focus on growth. Our admissions from Q4 to Q1 increased by 8.1%, with fee-for-service also growing 4% sequentially. Our year-over-year admission growth was up 0.7%. When normalized for leap year and the impact of our closed branches, growth is 2.5%. Our total home health census was down 2.4% year-over-year due to a low entry point in January. Sequentially, total census was up 3.7%.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Census growth occurred each month in Quarter 1, exiting March at an average daily census 9.8% higher than January. Our non-Medicare admissions were up 7.4% year-over-year, mainly driven by our payer innovation contracts. We increased the percentage of home health visits in payer innovation contracts. In the first quarter of 2024, 38% of non-Medicare visits were in payer innovation contracts. That rate grew to 44% in the first quarter of 2025. Payer mix progress to payer innovation contracts resulted in a 7.6% improvement year-over-year in non-Medicare revenue per visit. A just-right care plan for our patients continues to be an area of focus. With over two-thirds of our payer innovation contracts in episodic arrangements, managing our visits per episode while maintaining high-quality outcomes is an important part of our strategy. Total visits per episode declined 6.7% from 14.9 in Quarter 1 of 2024 to 13.9 in Quarter 1, 2025.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Continued progress with managing VPE creates additional clinical capacity, as evidenced by our decrease in cost per day, year-over-year, and sequentially. Moving now to our hospital segment, the sequential monthly census growth that started in January 2024 has continued throughout the first quarter of 2025. Total admissions grew 8% year-over-year, with same-store up 5.2%. Census grew 12.3%, with 10.6% same-store growth. Our admission departments continue to focus on timely responses to our referral sources, driving a 310 basis point improvement year-over-year in referrals to admission conversion. Census growth continues to create leverage on the fixed costs we added in 2023, resulting in a cost per day decrease of 0.8% year-over-year and a 2.7% decline sequentially. To complement our organic growth strategy, our de novo strategy is positively impacting total growth. In Quarter 1, we opened one hospital location and have 13 projects underway.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Turning now to our cost structure strategy update. As anticipated, we completed the transition of all branches to the outsourced coding resource in the first quarter, which we estimate will deliver $1.5 million in cost savings for the remainder of 2025. Additionally, seven branches were closed or consolidated in the first quarter, and four remain on track to be closed by the end of quarter two, 2025. We continue to focus on new technologies targeted at improving efficiency, productivity, and cost reduction. We are currently piloting two internally developed apps. One of these is designed to improve clinician and patient communication related to scheduled visits. The other is designed to improve communication between our business development and operation team members regarding patient referral to admission process and status. On the human capital front, we just completed our annual employee engagement survey with results above the healthcare benchmark.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

There were two drivers to our engagement success: our employees finding their work meaningful and collaborating with colleagues to deliver quality outcomes for our patients. Survey results are critical feedback to help focus management on priorities identified by our staff as important to their success and continued engagement. We are proud of our Enhabit culture and the impact it has on our teams and on our patients and their families. I will turn it over to Ryan, who will cover the financial results of Quarter 1.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Thanks, Barb. Q1 2025 financial performance delivered strong sequential growth, margin expansion, and continued deleveraging of our balance sheet. Execution in the quarter on our broader 2025 strategic priorities has enabled a strong start to 2025. A few highlights before reviewing the segments include the following: Home health performance returned the segment to sequential profitability growth in Q1, with segment EBITDA improving 7.9% sequentially, while also setting the stage for continued growth in 2025. Hospice momentum continues to be very strong, delivering year-over-year segment EBITDA growth of 65% on both ADC volume growth and margin expansion in Q1. The final highlight is our Q1 2025 leverage ratio of 4.4 times. This will allow us to benefit from improved pricing under our existing agreement and provide additional flexibility as we now exit our covenant release period restrictions under the agreement a quarter earlier than required.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Shifting to our detailed Q1 consolidated results, in the first quarter, consolidated net revenue was $259.9 million, an increase sequentially of $1.7 million or 0.7% quarter over quarter, while a decrease of $2.5 million or 1.0% year-over-year. Consolidated sequential revenue improvement reflects growth in both home health and hospice segments, with particular strength resulting from continued strong momentum in our hospice segment on both average daily census volume growth and favorable unit revenue. Consolidated revenue growth in the quarter translated into improved profitability sequentially, with consolidated adjusted EBITDA of $26.6 million in the quarter, an increase sequentially of $1.5 million or 6.0%, while growing to the prior year by $1.3 million or 5.1%, with overall EBITDA margin as a percentage of revenue coming in at 10.2%, an increase of 60 basis points to the prior year. Now shifting to our home health segment, performance for Q1.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Revenue came in at $200.6 million, an increase of $0.2 million or 0.1%. Volumes were up sequentially with a 3.7% increase in average daily census, somewhat muted by fewer calendar days in the quarter, leading to overall patient day volume growth of 1.4%. We saw growth in all payer types sequentially, with outsized growth in non-episodic volumes in the quarter, as we saw the benefit of a key national contract signed in December 2024. The growth in average daily census in the quarter allowed us to deliver a cost per patient day improvement of 3.1% sequentially, as we were able to improve clinical staff productivity on the additional volume. Home health adjusted EBITDA totaled $38.3 million in Q1, reflecting a sequential increase of $2.8 million or 7.9%.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

The breakdown of the $2.8 million of sequential improvement reflects $1.3 million related to volume, yield favorable by $1.0 million, and favorable sales ops back office and G&A related cost of $0.5 million. Q1 gross margin as a percentage of revenue came in at 48.5%, an improvement sequentially of 110 basis points, as we delivered lower cost per patient day on improving clinical staff productivity as we grew volumes in the quarter. We were able to pull this gross margin expansion through to adjusted EBITDA margin, finishing the quarter at 19.1%, an improvement of 140 basis points sequentially. A few key items to highlight in home health outside of our broader revenue and adjusted EBITDA performance include: a key priority in 2025 was slowing the rate of decline in our Medicare patient volumes.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Our teams were successful in executing on this strategy in the quarter, with Medicare ADC improving sequentially in Q1 to 20,110, an improvement of 1.5% on sequential admission growth of 4% representing back-to-back quarters of growth in this key metric. Combining ADC growth with our continued focus on optimizing productivity of our clinical staff and lower visits per episode allowed us to achieve a lower cost per patient day than what we saw in any quarter throughout full year 2024. Now shifting to our hospital segment. Revenue came in at $59.3 million, reflecting strong growth both sequentially increasing $1.5 million or 2.6%, and to prior year increasing $10.1 million or 20.5%. Volume growth remained strong, with average daily census totaling 3,809 in Q1, an improvement of 2.1% sequentially and 12.3% year-over-year.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Q1 2025 unit revenue per patient day benefited from the reversal of aged Medicare cap liability of approximately $1.0 million, which after normalizing for this benefit in the quarter, we would have seen relatively flat unit revenue sequentially. Hospice adjusted EBITDA totaled $15.0 million in Q1, reflecting a sequential increase of $1.7 million or 12.8% on increased revenues combined with gross margin expansion of 260 basis points, as we saw improved unit cost per patient day on increased volumes. A few key items to highlight in hospice outside of broader revenue and adjusted EBITDA performance include: hospice adjusted EBITDA margin as a percentage of revenue at 25.3% in Q1 reflects five straight quarters of sequential improvement, and the highest adjusted EBITDA as a percentage of revenue for this segment post-spend, as our operational leadership continues to realize leverage benefits from average daily census growth.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Growth in average daily census combined with a lower average length of stay sequentially and year-over-year continues to lower our overall cap liability risk. Shifting to our home office and general and administrative expenses totaled $26.7 million or 10.3% of revenues in Q1, a decrease of $0.3 million or 1.1% year-over-year. This decrease reflects targeted cost savings initiatives somewhat offset by merit and other inflationary increases year-over-year. Transitioning now to the balance sheet and cash flow. A key strategic priority in 2025 is using free cash flow to continue to deleverage our balance sheet. In Q1, we generated approximately $17 million of free cash flow, a 63.5% free cash flow conversion rate. During the quarter, we reduced our overall bank debt by $25 million.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

We did this through the combination of free cash flow generation and utilization of $20 million in proceeds from the sale of our investment interest in Metalogyx. We ended the quarter with approximately $40 million in cash, a $12 million sequential improvement. Additionally, our liquidity increased approximately $30 million sequentially to $111 million. Improved profitability coupled with these balance sheet improvements results in a leverage ratio now of 4.4 times, which is below our covenant of 4.5 times. Later today, we will deliver the Q1 covenant certificate to our lender group, which will effectively end the covenant release period we entered in Q4 2023. Since Q4 2023, we have successfully lowered our leverage by one full turn. A meaningful benefit of exiting the release period is improved pricing under our existing agreement and added flexibility around tuck-in acquisitions. We remain committed to strengthening our balance sheet and improving profitability.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Now let's briefly turn to guidance. Based on our consolidated first quarter results and the momentum in the business, we reaffirm our 2025 guidance. Thank you for the time today. Operator, could you please open the line for questions?

[Operator]

Thank you. If you would like to ask a question, please press star and the number one on your telephone keypad. With our first question, this comes from the line of Brian Tanquilut from Jefferies. The line's open.

[Brian Tanquilut, Senior Equity Research Analyst at Jefferies]

Hi, good morning, and congrats on the quarter. Barb, maybe as I think about the performance in Q1, and as we think about the United contract coming in, I mean, how are you thinking about the ramp in further volume growth within the non-Medicare book of business, especially as we give consideration to, in theory, volumes coming through that, specific clients?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Sure. I think first, you know, just to note that, you know, obviously the goal of the field is really to balance admissions to make sure we maintain a very healthy payer mix. When we look at, you know, obviously we had, you know, negative growth year-over-year in Medicare. The areas that we positively grew were payer innovation and some of the other contracts outside of payer innovation. Payer innovation was 82% of that positive growth. So, you know, that really shows that the field is doing a good job balancing that. The focus now really is now continuing our hiring, so that we can continue to improve that average daily census and those admissions.

[Brian Tanquilut, Senior Equity Research Analyst at Jefferies]

Got it. As I think about the labor profile or the labor market in the business lines that you run, how should we be thinking about, you know, kind of like the inflation expectation for the rest of the year?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Sure. We do believe that we're kind of back to that, you know, normal of that, you know, 2-3% in a salary, market, and merit. There are some markets where it is becoming a little bit more difficult, and we're going to, we're focusing on those at a market level to see if there's additional compensation adjustments that need to occur.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Brian, with that, I think we're also demonstrating the ability with normalized market rates to build capacity. Building on Barb's point earlier, we were able to grow our capacity from December to March by approximately 4%. We're really feeling good about the market normalizing and then the ability to build capacity behind that, to set us up for growth through the balance of the year.

[Brian Tanquilut, Senior Equity Research Analyst at Jefferies]

Perfect. Thank you.

[Operator]

Thank you. Our next question comes from the line of A.J. Rice from UBS. The line's open.

[A.J. Rice, Managing Director at UBS]

Hi. Hi, everybody. First, on the hospice side, obviously the ADC growth has been, is really good there. What, is that you specifically, initiatives you're putting on, gaining share, or do you think there's underlying, you know, improvement in the overall market that's somehow helping drive that?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

I think it is a combination. I mean, our referrals were up in first quarter year-over-year about 3%. If you recall, last year we put in regional admissions departments so that we can have a very quick and timely answer to our referral sources. I do think that has helped the conversion rate. Our conversion rate was up 310 basis points. Our conversion rate is, you know, 79%. It was a nice strong conversion rate on those referrals. I think it is a combination of the referrals, but also on some of the work that we've put into that timely response.

[A.J. Rice, Managing Director at UBS]

Okay. Maybe obviously one of the areas on home health is your business per episode continues to trend in a good direction there. Maybe touch out some of the dynamics behind that or the newer contracts allowing you more flexibility on business per episode. Are there other things you're doing that are driving that?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

The continued use of Metalogyx Pulse has been the critical piece to the visit per episode, you know, really making sure that we're giving those higher number of visits to the higher acuity patients and moving visits away from patients that, you know, either have less acuity or that have progressed quicker than anticipated, and really adjusting that plan of care so that those can either be moved to a new patient or to a patient of higher acuity. It is that continued focus on the Metalogyx Pulse tool at the field level.

[A.J. Rice, Managing Director at UBS]

Okay. All right. Are you pretty much fully penetrated on the Metalogyx, just to put a finer point on that?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Yeah. So that's in all of the branches, and we continue to, you know, work with the branch directors to make sure that it's being utilized as intended.

[A.J. Rice, Managing Director at UBS]

Okay. All right. Thanks a lot.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Thank you.

[Operator]

Thank you. Our next question comes from the line of Ryan Langston from TD Cowen. The line's open.

[Ryan Langston, Director and Senior Analyst of Healthcare Research at TD Cowen]

Great. Thank you. Sticking with hospice, you know, obviously nice growth, cost per patient day down 80 basis points. I know you've centralized some of the operations there. I guess how much ability is left to sort of, sort of leverage those operations? I mean, if ADC keeps growing nicely, like it really has, at some point, are you going to have to make sort of a step investment in those operations just to support all this new growth?

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Yeah. Ryan, good morning. Thanks for the question. I think ultimately, you know, as we think about that, we've done a really good job, to your point, of really creating the leverage and kind of improvement in profitability. You know, I think as far as, you know, investment and kind of how do we think about that going forward, you know, when we look at the margin profile, it was really healthy in Q1. We think that we've started to kind of, you know, fully generate the leverage profile on the volume. There will be, you know, what I'll call minor incremental investments as we kind of go through those step function growth phases, but we wouldn't anticipate a material deviation from the margin profile that we saw, you know, really in Q4, continued into Q1.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

We'll continue to monitor that, but it feels like we're in a pretty good glide slope from an overall margin profile, along with the growth trajectory that we're on.

[Ryan Langston, Director and Senior Analyst of Healthcare Research at TD Cowen]

Got it. And then just, you know, obviously the growth has been very impressive. I think it's 14 months of straight ADC growth in hospice. I guess where are you running from a capacity and sort of productivity standpoint in terms of sort of on-the-ground labor? And I guess, is there any reason we shouldn't sort of assume that this ADC growth won't continue through the rest of the year? Thanks.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

First, from the capacity standpoint, that really is kind of at a branch level. You know, we do look to make sure that we have the capacity to grow at our branches. And so because we're on this case management model, you know, you can really start to grow into that case management model while adding additional resources, but ensuring that you have that referral flow coming in so that you can have that strong productivity that we've seen. You know, I do think, again, because of the work that we've done to diversify the referral sources, and the focus on the admissions departments, we don't, you know, anticipate any change in our growth trajectory.

[Ryan Solomon, CFO at Enhabit Home Health and Hospice]

Yeah. Maybe just to build on that, you know, if we look at our ADC growth up year-over-year at 12.3%, if we look at the RN capacity that we had exiting March, year-over-year, we were up 16%. To build on Barb's point, I think we're staying ahead of the curve from an overall kind of RN and capacity in front of our volume. We feel confident that, you know, the team's executing at a really high level. We've got a really strong operating team in the hospice segment, and we have a lot of confidence they'll continue to execute there.

[Ryan Langston, Director and Senior Analyst of Healthcare Research at TD Cowen]

That's great. Thank you.

[Operator]

Thank you. Again, if you'd like to have a question or if you have further questions, please press star and the number one on your telephone keypad. Our next question comes from the line of Whit Mayo from Leerink Partners. The line's open.

[Whit Mayo, Senior Managing Director of Healthcare Providers and Managed Care at Leerink Partners]

Hey, thanks. Hey, Barb, I'm just curious now that you're lapping sort of a year or two of some of the original contracts from plans on your payer innovation strategy, what the rate increases are looking like? Or do you have annual rate escalators or anything on these contracts? Is there, you know, any protection you have around, you know, keeping up with inflation that would be helpful?

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Sure. Most of our contracts are two to three years in length. We do right now have 43 in our pipeline that we're working on the renegotiations. A few do have escalators. Some of them are tied to quality metrics. We do bring a lot of data to show not only what has happened from an inflationary impact, but we kind of know on the flip side what Medicare Advantage has been receiving from CMS. We like to bring a lot of that data to the table as we work to renegotiate, to move to not only better pricing, but continue to try to shift to more episodic payers.

[Whit Mayo, Senior Managing Director of Healthcare Providers and Managed Care at Leerink Partners]

Thanks. Maybe just on research, the research just keeps declining. I thought you seemed fairly confident that you had some initiatives that would start to stem some of those losses and maybe reverse itself. Maybe some color around the recertification rates. Thanks.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Sure. You know, we do follow how we are compared to others in our home care home-based system. We still are within, in fact, a little bit above kind of our peers in home care home-based. Our focus has really been on, you know, using Metalogyx Pulse that will do a recommendation on whether the patient looks like they're going to need a recert. You know, making sure that in the team meetings they're discussing those patients that could benefit. We have obviously seen, as Medicare Advantage grows, even if we believe the patient needs a recert, we're not always successful in getting that recert. The focus has really been on growing census, because ultimately that's going to be the driver, whether that's through admissions or recert.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

We've also put a little bit of more focus on early institutional, which does have, you know, higher revenue, but the early institutional does not have the same research potential that more of your chronic community-based patients have. We are seeing a little bit of the research impact, based on the blend of the admissions we're getting.

[Whit Mayo, Senior Managing Director of Healthcare Providers and Managed Care at Leerink Partners]

Thanks.

[Barb Jacobsmeyer, President and CEO at Enhabit Home Health and Hospice]

Thanks.

[Operator]

Thank you. There are no further questions. I'll be turning the call back over now to Jobie Williams for closing remarks.

[Jobie Williams, SVP and Treasurer at Enhabit Home Health and Hospice]

If you have any additional questions, please email investorrelations@enhabit.com. Thank you again for joining today's call.

Participants

Executives

• Jobie Williams, SVP and Treasurer
• Barb Jacobsmeyer, President and CEO
• Ryan Solomon, CFO

Analysts

• Brian Tanquilut, Senior Equity Research Analyst at Jefferies
• Whit Mayo, Senior Managing Director of Healthcare Providers and Managed Care at Leerink Partners
• Ryan Langston, Director and Senior Analyst of Healthcare Research at TD Cowen
• A.J. Rice, Managing Director at UBS